Investigating how SETD2 gene changes affect lung cancer driven by EGFR and KRAS mutations
Paradoxical Effects of SETD2 Inactivation in EGFR- and KRAS-driven Lung Adenocarcinoma
This study is looking at how certain gene changes in lung cancer, especially the SETD2 gene, work together with other mutations to affect tumor growth, and it hopes to find new ways to treat patients based on their unique genetic makeup.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11088872 on NIH RePORTER |
What this research studies
This research explores the complex interactions between genetic mutations in lung adenocarcinoma, particularly focusing on the SETD2 gene and its effects when paired with other mutations like KRAS and EGFR. The study aims to understand how the inactivation of SETD2 can lead to different outcomes in tumor growth depending on the presence of other mutations. By examining these relationships, the research seeks to identify new therapeutic strategies that could exploit these genetic interactions to improve cancer treatment. Patients with specific genetic profiles may benefit from insights gained through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with lung adenocarcinoma who have mutations in the KRAS or EGFR genes.
Not a fit: Patients without lung adenocarcinoma or those whose tumors do not have mutations in KRAS or EGFR may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for lung cancer that are more effective based on individual genetic profiles.
How similar studies have performed: Previous research has shown promising results in understanding genetic interactions in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Doerig, Katherine — University of Pennsylvania
- Study coordinator: Doerig, Katherine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.